Ozempic and Thyroid Cancer

In 2021, Ozempic (semaglutide) emerged as one of the most widely prescribed medications in the United States, with over 9 million prescriptions recorded in the last quarter of 2022 alone. By 2035, projections suggest that the number of prescriptions could soar to 24 million annually in the U.S. The medication has shown remarkable effectiveness in helping manage type 2 diabetes and aiding weight loss, making it a critical tool for millions of individuals striving to improve their health outcomes. However, as its usage grows, so do questions surrounding its long-term safety—particularly regarding its potential effects on thyroid health.

In this article, you will learn about the possible connections between Ozempic and thyroid cancer, how it may impact thyroid function, and who might need to avoid this medication. So, let’s get started!

Has Anyone Gotten Thyroid Cancer from Semaglutide?

To date, no direct evidence conclusively links Ozempic (semaglutide) to thyroid cancer in humans. However, concerns stem from animal studies where semaglutide was shown to cause thyroid C-cell tumors in rodents. These findings raise questions about whether similar risks might apply to humans.

Human studies, so far, present mixed results. One large observational study in Europe compared thyroid cancer rates in individuals using semaglutide with those who did not. A slight increase in thyroid cancer was observed among semaglutide users over a 1 to 3-year period. However, this difference was not statistically significant and could have been influenced by other factors, such as pre-existing conditions, family history, or environmental exposures.

Another comprehensive review of clinical trial data found no significant association between semaglutide and thyroid cancer. This review included thousands of participants and spanned several years of drug use. Regulatory bodies like the European Medicines Agency have also reviewed the data and concluded that there is no confirmed link between semaglutide and thyroid cancer in humans.

Despite the lack of conclusive evidence, safety guidelines recommend avoiding Ozempic in individuals with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2). This caution is due to the results seen in animal studies and the potential for unknown risks.

How Does Ozempic Affect Thyroid Function?

Ozempic interacts with the body through its action as a GLP-1 receptor agonist. While its primary function is to regulate blood sugar levels and promote weight loss, there is ongoing research into how it affects the thyroid gland.

In rodent studies, semaglutide was linked to the development of thyroid tumors, including medullary thyroid carcinoma. This connection is thought to be mediated through the activation of GLP-1 receptors in thyroid C-cells. However, these receptors are less active in human thyroid tissue, which may explain why similar effects have not been conclusively observed in human studies.

Human data indicate that semaglutide does not significantly increase the risk of common thyroid conditions, such as:

• Hyperthyroidism: Overactivity of the thyroid gland leads to excessive hormone production.

• Hypothyroidism: Underactivity of the thyroid gland, causing insufficient hormone production.

• Thyroiditis: Inflammation of the thyroid gland.

• Goiter or Nodules: Swelling or growths in the thyroid that are typically benign.

Although current findings suggest a low likelihood of significant thyroid effects in humans, the rodent data underline the need for continued monitoring, particularly in individuals with predisposing risk factors.

Can You Take Ozempic When You Have Cancer?

Whether you can take Ozempic (semaglutide) when you have cancer depends on several factors, including the type and stage of cancer, your overall treatment plan, and how Ozempic may interact with your condition.

Ozempic is generally not recommended for individuals with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2) due to findings in animal studies suggesting an increased risk of thyroid tumors. For other types of cancer, the decision to continue or discontinue Ozempic is often based on the potential for overlapping side effects. For instance, cancer treatments frequently cause nausea, vomiting, and appetite changes, which are also common side effects of Ozempic. Combining these effects could worsen symptoms and negatively impact your quality of life.

Preliminary research suggests that semaglutide might have some effects on natural killer cells, which play a role in identifying and destroying abnormal cancer cells. However, this is an emerging area of study and not part of standard cancer treatment protocols. Currently, Ozempic is not approved as a cancer treatment or as a therapy for cancer-related conditions.

If you are undergoing cancer treatment, it’s essential to evaluate whether Ozempic aligns with your overall care plan. In many cases, the potential risks and benefits of continuing Ozempic must be carefully weighed, considering your specific medical needs and treatment goals.

Who Shouldn’t Take Ozempic?

Ozempic is not suitable for everyone, and certain individuals should avoid taking it due to potential risks. The following groups are advised against using Ozempic:

• Personal or Family History of Medullary Thyroid Carcinoma (MTC): Research in rodent models has shown that semaglutide can cause thyroid C-cell tumors. While this has not been conclusively observed in humans, individuals with a history of MTC or a genetic predisposition to multiple endocrine neoplasia type 2 (MEN 2) are advised to avoid the drug as a precaution.

• Known Allergies to Semaglutide or Its Ingredients: Anyone with a history of severe allergic reactions (anaphylaxis) to semaglutide or any component of Ozempic should not use it. Signs of an allergic reaction may include difficulty breathing, swelling, and severe skin reactions.

• Severe Gastrointestinal Disorders: Ozempic slows digestion, which can exacerbate conditions such as gastroparesis (delayed stomach emptying). People with severe or chronic gastrointestinal issues should avoid using this medication.

• Pregnancy or Planning to Become Pregnant: Ozempic is not recommended during pregnancy due to potential risks to the fetus. Women who are planning to conceive should discontinue the medication at least two months prior to trying to become pregnant.

• Pancreatitis History: Although the connection is not definitive, Ozempic has been associated with cases of acute pancreatitis in some individuals. Those with a history of pancreatitis should use caution and may need to avoid the drug entirely.

• Severe Kidney Impairment: While not directly nephrotoxic, Ozempic can cause dehydration due to side effects like vomiting or diarrhea, which may worsen kidney function in individuals with existing kidney issues.

• Personal Intolerance of Side Effects: Some people experience severe side effects, including persistent nausea, vomiting, or diarrhea, which can significantly impact quality of life. In such cases, discontinuing the medication may be necessary.

What Happens if You Get Cancer After Taking Ozempic?

If you are diagnosed with cancer while taking Ozempic (semaglutide), the decision to continue or discontinue the medication depends on the type of cancer, its treatment, and potential interactions with Ozempic. In cases of thyroid cancer, particularly medullary thyroid carcinoma (MTC), stopping Ozempic is generally advised due to its known effects on thyroid C-cells in animal studies.

For other types of cancer, factors such as the drug’s side effects—like nausea and slowed digestion—may overlap with symptoms caused by cancer treatments, making Ozempic less suitable. The FDA monitors adverse effects through its reporting system, and individuals diagnosed with cancer while using Ozempic may consider filing a report to contribute to ongoing safety evaluations.

Final Thoughts

Ozempic has proven effective in managing type 2 diabetes and aiding weight loss, but concerns about its potential link to thyroid cancer warrant careful consideration. While human studies have not confirmed a direct connection, individuals with a history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 should avoid using it. For most users, the benefits outweigh the risks, but long-term studies are needed to provide more clarity.

Frequently Asked Questions